Deadline Approaching: Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [e-mail], by telephone at [phone] or visit our website at www.howardsmithlaw.com.

What Happened?

On February 23, 2026, Gossamer disclosed that results for its Phase 3 PROSERA study of seralutinib for the treatment of pulmonary arterial hypertension had failed to meet the primary endpoint, citing patients at Latin American sites performing particularly well on placebo due to enrollment of a heavily-treated lower-risk population.

On this news, Gossamer’s stock price fell $1.71, or 80.3%, to close at $0.42 per share on February 23, 2026, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) patients at the Latin American sites were largely heavily-treated and lower risk and, ultimately, performed particularly well on the placebo, thus, Gossamer’s Phase 3 PROSERA study failed to meet the primary endpoint of improved six-minute walk distance at week 24; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Gossamer securities during the Class Period, you may move the Court no later than June 1, 2026 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements.

Contact Us To Participate or Learn More:

If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith
3070 Bristol Pike, Suite 112
Bensalem, Pennsylvania 19020
Telephone: [phone]
Email: [e-mail]
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.